PMID- 21671171
OWN - NLM
STAT- MEDLINE
DCOM- 20130502
LR  - 20211020
IS  - 1672-0733 (Print)
IS  - 1672-0733 (Linking)
VI  - 31
IP  - 3
DP  - 2011 Jun
TI  - Telmisartan protects against insulin resistance by attenuating inflammatory 
      response in rats.
PG  - 317-323
LID - 10.1007/s11596-011-0374-7 [doi]
AB  - This study investigated the effects of telmisartan on insulin resistance in 
      high-fat diet-treated rats and the possible mechanism. A total of 40 male 
      Sprague-Dawley rats enrolled in the study were divided into 4 groups at random: 
      ND group (n=10) and HD group (n=10), in which the rats were given a normal chow 
      diet or a high-fat diet for 20 weeks following a one-week adaptation; 
      ND+telmisartan (n=10) group and HD+telmisartan group (n=10), in which the rats 
      were initially administered in the same way as the ND or HD group, and then they 
      were orally gavaged with telmisartan (5 mg/kg daily) additionally for 5 weeks. 
      Related inflammatory factors were measured by ELISA. Monocyte chemotactic protein 
      1 (MCP-1), phosphorylated JNK and IkappaB-alpha expressions in both adipose and liver 
      were detected by Western blotting. CRP and angiotensin II receptor 1 (AT1) mRNA 
      expressions in both adipose and liver were determined by RT-PCR. The results 
      showed that telmisartan administration in vivo reversed insulin resistance as 
      evidenced by a decrease in plasma fasting glucose levels, plasma fasting insulin 
      levels and homeostasis model of assessment-insulin resistance (HOMA-IR). 
      Furthermore, telmisartan administration significantly reduced serum CRP, TNF-alpha 
      and IL-1beta levels, and elevated serum IL-10 levels. It was also found to hamper 
      the high-fat diet-induced increase in CRP mRNA, AT1 mRNA and MCP-1, and decrease 
      in IkappaB-alpha in both adipose and liver. It was concluded that telmisartan 
      administration in vivo may improve insulin resistance through attenuated 
      inflammatory response pathways.
FAU - Xu, Xizhen
AU  - Xu X
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China.
FAU - Yin, Xiaoming
AU  - Yin X
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China.
FAU - Feng, Wenjing
AU  - Feng W
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China.
FAU - Li, Geng
AU  - Li G
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China.
FAU - Wang, Daowen
AU  - Wang D
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China.
FAU - Tu, Ling
AU  - Tu L
AD  - Department of Internal Medicine and the Institute of Hypertension, Tongji 
      Hospital, Tongji Medical College, Huazhong University of Science and Technology, 
      Wuhan, 430030, China. proftu@tom.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110614
PL  - China
TA  - J Huazhong Univ Sci Technolog Med Sci
JT  - Journal of Huazhong University of Science and Technology. Medical sciences = Hua 
      zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. 
      Yixue Yingdewen ban
JID - 101169627
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Dietary Fats)
RN  - 0 (I-kappa B Proteins)
RN  - 0 (Nfkbia protein, rat)
RN  - 0 (RNA, Messenger)
RN  - 0 (Receptor, Angiotensin, Type 1)
RN  - 139874-52-5 (NF-KappaB Inhibitor alpha)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*pharmacology
MH  - Animals
MH  - Benzimidazoles/*pharmacology
MH  - Benzoates/*pharmacology
MH  - C-Reactive Protein/metabolism
MH  - Chemokine CCL2/metabolism
MH  - Cytokines/blood
MH  - Dietary Fats/administration & dosage
MH  - I-kappa B Proteins/metabolism
MH  - Inflammation/*prevention & control
MH  - *Insulin Resistance
MH  - Male
MH  - NF-KappaB Inhibitor alpha
MH  - RNA, Messenger/genetics/metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptor, Angiotensin, Type 1/metabolism
MH  - Telmisartan
EDAT- 2011/06/15 06:00
MHDA- 2013/05/03 06:00
CRDT- 2011/06/15 06:00
PHST- 2010/11/24 00:00 [received]
PHST- 2011/06/15 06:00 [entrez]
PHST- 2011/06/15 06:00 [pubmed]
PHST- 2013/05/03 06:00 [medline]
AID - 10.1007/s11596-011-0374-7 [pii]
AID - 10.1007/s11596-011-0374-7 [doi]
PST - ppublish
SO  - J Huazhong Univ Sci Technolog Med Sci. 2011 Jun;31(3):317-323. doi: 
      10.1007/s11596-011-0374-7. Epub 2011 Jun 14.